{"id":31580,"date":"2025-05-02T17:35:00","date_gmt":"2025-05-02T12:05:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31580"},"modified":"2025-10-09T16:59:51","modified_gmt":"2025-10-09T11:29:51","slug":"miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","title":{"rendered":"New Era in Niemann-Pick Disease: A Comparative Review of MIPLYFFA and AQNEURSA"},"content":{"rendered":"\n

Niemann-Pick disease type C (NPC) is a rare, aggressive, and life-threatening neurovisceral disorder with a profound impact on both patients and the healthcare system. Caused by mutations in the NPC1 or NPC2 genes, NPC disrupts intracellular lipid transport, leading to toxic accumulation of cholesterol and other lipids, especially in the brain and visceral organs. The disease\u2019s complexity, variability in presentation, and lack of early biomarkers result in frequent misdiagnosis and delayed care. With a reported incidence of 1 in 100,000\u2013120,000 live births<\/strong> (NORD), the true prevalence is likely underestimated. The burden of long-term supportive care, repeated hospitalizations, and the absence of curative treatment of NPC puts considerable strain on healthcare systems. NPC’s devastating progression and unmet clinical needs present a compelling opportunity for biopharmaceutical innovation. <\/p>\n\n\n\n

This article examines the impact of two newly approved therapies for Niemann-Pick disease type C treatment<\/a>\u2014MIPLYFFA <\/strong>and AQNEURSA<\/strong>\u2014offering a comparative analysis of their cost-effectiveness and clinical use.<\/p>\n\n\n\n

\u200bUntil 2024, therapeutic options for NPC were limited, with no definitive cure available for any type, and the treatments were largely supportive and focused on managing symptoms and improving quality of life. Recent advancements in the treatment of NPC mark a major turning point in the management of this rare and life-limiting disorder. In a historic move, the U.S. Food and Drug Administration (FDA) approved two distinct Niemann-Pick disease type C therapies<\/a> in close succession: MIPLYFFA (arimoclomol)<\/strong> and AQNEURSA (levacetylleucine)<\/strong>. These approvals represent a significant shift from purely supportive care to disease-modifying options to slow neurological decline. <\/p>\n\n\n\n

MIPLYFFA<\/strong>, developed by Zevra Therapeutics<\/strong> and approved on September 20, 2024, is indicated for patients aged two years and older. It functions as a heat shock protein (HSP) amplifier, enhancing lysosomal activity and stabilizing misfolded proteins, particularly within the NPC1 pathway. Its efficacy is maximized when used in combination with miglustat, and clinical data show a meaningful reduction in neurological disease progression.AQNEURSA<\/strong>, developed by IntraBio<\/strong> and approved shortly after on September 24, 2024, is the first monotherapy approved for NPC in patients aged four years and older and weighing \u226515 kg. This modified amino acid targets cellular energy metabolism and neuronal signaling, offering a flexible treatment option, particularly for patients who cannot tolerate combination regimens. Trials demonstrated significant improvements in motor coordination and other neurological functions.<\/p>\n\n\n\n

<\/span><\/p>\n

\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Comparative Analysis of MIPLYFFA and AQNEURSA<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Parameters<\/span><\/p>\n<\/td>\n

\n

MIPLYFFA (arimoclomol)<\/span><\/p>\n<\/td>\n

\n

AQNEURSA (Levacetylleucine)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

FDA Approval Date<\/span><\/p>\n<\/td>\n

\n

20 September 2024<\/span><\/p>\n<\/td>\n

\n

24 September 2024<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Company<\/span><\/p>\n<\/td>\n

\n

Zevra Therapeutics<\/span><\/p>\n<\/td>\n

\n

IntraBio<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Indication<\/span><\/p>\n<\/td>\n

\n

Neurological manifestations in NPC (ages ≥2) in combination with miglustat<\/span><\/p>\n<\/td>\n

\n

Neurological manifestations in NPC (≥15kg)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Formulation<\/span><\/p>\n<\/td>\n

\n

Capsule<\/span><\/p>\n<\/td>\n

\n

Suspension<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

ROA<\/span><\/p>\n<\/td>\n

\n

Oral<\/span><\/p>\n<\/td>\n

\n

Oral<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Dosage<\/span><\/p>\n<\/td>\n

\n

Recommended dose as per body weight<\/span><\/p>\n

– <\/span>8 kg to 15 kg<\/span>, is 47 mg three times a day<\/span><\/p>\n

– <\/span>>15 kg to 30 kg<\/span>, is 62 mg three times a day<\/span><\/p>\n

– <\/span>>30 kg to 55 kg<\/span>, is 93 mg three times a day<\/span><\/p>\n

– <\/span>>55 kg, <\/span>is 124 mg three times a day<\/span><\/p>\n<\/td>\n

\n

Recommended dose as per body weight<\/span><\/p>\n

– <\/span>15 kg to 25 kg<\/span>, 1gm twice daily<\/span><\/p>\n

– <\/span>25 kg to 35 kg<\/span>, is 1gm three times a day<\/span><\/p>\n

– <\/span>>35 kg<\/span>, 4gm daily (2gm in the morning, 1gm in afternoon, and 1gm in the evening)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Efficacy<\/span><\/p>\n<\/td>\n

\n

Efficacy Measure:<\/span> R4DNPCCSS (assesses ambulation, speech, swallow, and fine motor skills) <\/span>
<\/span>It slowed down the progression of the disease. The mean baseline R4DNPCCSS score was higher in the MIPLYFFA group (n=26; mean=8.9) than the placebo group (n=13; mean=7), with an overall mean R4DNPCCSS score of 8.3.<\/span><\/p>\n<\/td>\n

\n

Efficacy Measure:<\/span> Functional SARA (fSARA) — gait, stance, sitting, speech disturbances<\/span><\/p>\n

The fSARA score was assessed at baseline, 6 weeks, 12 weeks, 18 weeks, and 24 weeks. The estimated mean fSARA total score was 5.1 when patients were treated with AQNEURSA and 5.6 when patients were treated with placebo. The estimated treatment difference for the fSARA total score was -0.4.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Safety<\/span><\/p>\n<\/td>\n

\n

Most common adverse reactions (≥15%): upper respiratory tract infection, diarrhea, and decreased weight.<\/span><\/p>\n<\/td>\n

\n

Most common adverse reactions (incidence ≥5% and greater than placebo): abdominal pain, dysphagia, upper respiratory tract infections, and vomiting.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Designations<\/span><\/p>\n<\/td>\n

\n

Priority Review, Orphan Drug, Fast Track, Breakthrough, Rare Pediatric Disease designations<\/span><\/p>\n<\/td>\n

\n

Priority Review, Orphan Drug, Fast Track, Rare Pediatric Disease designations<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Average annual cost to the patient<\/span><\/p>\n<\/td>\n

\n

USD 503,600 to USD 1,328,000<\/span><\/p>\n<\/td>\n

\n

USD 366,350 to USD 732,650<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Clinical Impact and Future Directions in Niemann-Pick Disease Treatment<\/strong><\/p>\n\n\n\n

The FDA approvals of MIPLYFFA<\/strong> and AQNEURSA<\/strong> represent a groundbreaking milestone in the treatment landscape for NPC<\/a>, offering much-needed therapeutic options tailored to individual patient profiles. MIPLYFFA, used alongside miglustat, may be more appropriate for patients already on miglustat therapy, while AQNEURSA stands out as a viable and more affordable monotherapy alternative. Early intervention with either drug may significantly improve neurological outcomes and extend life expectancy, which typically averages just 13 years in NPC patients. From a market perspective, given AQNEURSA’s affordability and wider therapeutic reach,<\/strong> DelveInsight estimates projected peak U.S. sales of USD 500 million<\/strong>, compared to USD 300 million<\/strong> for MIPLYFFA. These approvals signify a major leap forward in rare disease innovation, emphasizing the growing importance of combination strategies, individualized dosing, and early diagnosis. Moving ahead, post-marketing surveillance and real-world clinical data will be essential in optimizing therapeutic outcomes, especially within pediatric populations and across long-term disease management.<\/p>\n\n\n\n

\"Niemann-Pick<\/a><\/figure>\n\n\n\n

FAQs<\/h2>\n\n\n\n
What are the current NPC treatment options?<\/strong><\/strong>

\u200bUntil 2024, therapeutic options for NPC were limited, with no definitive cure available for any type, and the treatments were largely supportive and focused on managing symptoms and improving quality of life. In a historic move, the FDA approved two distinct Niemann-Pick disease type C therapies in close succession: MIPLYFFA and AQNEURSA.<\/p> <\/div>

How do MIPLYFFA and AQNEURSA differ in their mechanisms of action?<\/strong><\/strong>

MIPLYFFA enhances the function of heat shock proteins, aiding in the proper folding of proteins and promoting the clearance of accumulated lipids within cells. On the other hand, AQNEURSA targets mitochondrial function, aiming to improve cellular energy production and reduce the accumulation of lipids.<\/p> <\/div>

How do MIPLYFFA and AQNEURSA differ in their administration?<\/strong><\/strong>

MIPLYFFA is taken orally three times daily in combination with miglustat. Whereas, AQNEURSA is also taken orally up to three times per day, with or without food. The dosage varies based on the patient’s body weight.<\/p> <\/div>

Can MIPLYFFA and AQNEURSA be used together?<\/strong><\/strong>

No, the FDA has not approved the combination of MIPLYFFA and AQNEURSA for the treatment of NPC.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"

Niemann-Pick disease type C (NPC) is a rare, aggressive, and life-threatening neurovisceral disorder with a profound impact on both patients and the healthcare system. Caused by mutations in the NPC1 or NPC2 genes, NPC disrupts intracellular lipid transport, leading to toxic accumulation of cholesterol and other lipids, especially in the brain and visceral organs. The […]<\/p>\n","protected":false},"author":14,"featured_media":31583,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22540,22539,21410,21409,21414,21412,21413,21411],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-31580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aqneursa","tag-miplyffa","tag-niemann-pick-disease","tag-niemann-pick-disease-type-c-2","tag-niemann-pick-disease-type-c-clinical-trials","tag-niemann-pick-disease-type-c-market","tag-niemann-pick-disease-type-c-pipeline","tag-niemann-pick-disease-type-c-treatment","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"\nMIPLYFFA vs. AQNEURSA in Niemann-Pick Disease | Key Insights<\/title>\n<meta name=\"description\" content=\"Dive deep into the impact of two newly approved therapies for Niemann-Pick disease type C treatment\u2014MIPLYFFA and AQNEURSA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MIPLYFFA vs. AQNEURSA in Niemann-Pick Disease | Key Insights\" \/>\n<meta property=\"og:description\" content=\"Dive deep into the impact of two newly approved therapies for Niemann-Pick disease type C treatment\u2014MIPLYFFA and AQNEURSA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-02T12:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T11:29:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MIPLYFFA vs. AQNEURSA in Niemann-Pick Disease | Key Insights","description":"Dive deep into the impact of two newly approved therapies for Niemann-Pick disease type C treatment\u2014MIPLYFFA and AQNEURSA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"MIPLYFFA vs. AQNEURSA in Niemann-Pick Disease | Key Insights","og_description":"Dive deep into the impact of two newly approved therapies for Niemann-Pick disease type C treatment\u2014MIPLYFFA and AQNEURSA.","og_url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-02T12:05:00+00:00","article_modified_time":"2025-10-09T11:29:51+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","name":"MIPLYFFA vs. AQNEURSA in Niemann-Pick Disease | Key Insights","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment.png","datePublished":"2025-05-02T12:05:00+00:00","dateModified":"2025-10-09T11:29:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Dive deep into the impact of two newly approved therapies for Niemann-Pick disease type C treatment\u2014MIPLYFFA and AQNEURSA.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009337700"},{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009354755"},{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009365638"},{"@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009377337"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment.png","width":466,"height":284,"caption":"miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009337700","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009337700","name":"What are the current NPC treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"\u200bUntil 2024, therapeutic options for NPC were limited, with no definitive cure available for any type, and the treatments were largely supportive and focused on managing symptoms and improving quality of life. In a historic move, the FDA approved two distinct Niemann-Pick disease type C therapies in close succession: MIPLYFFA and AQNEURSA.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009354755","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009354755","name":"How do MIPLYFFA and AQNEURSA differ in their mechanisms of action?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MIPLYFFA enhances the function of heat shock proteins, aiding in the proper folding of proteins and promoting the clearance of accumulated lipids within cells. On the other hand, AQNEURSA targets mitochondrial function, aiming to improve cellular energy production and reduce the accumulation of lipids.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009365638","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009365638","name":"How do MIPLYFFA and AQNEURSA differ in their administration?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"MIPLYFFA is taken orally three times daily in combination with miglustat. Whereas, AQNEURSA is also taken orally up to three times per day, with or without food. The dosage varies based on the patient's body weight.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009377337","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment#faq-question-1760009377337","name":"Can MIPLYFFA and AQNEURSA be used together?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"No, the FDA has not approved the combination of MIPLYFFA and AQNEURSA for the treatment of NPC.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/02103221\/miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AQNEURSA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MIPLYFFA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AQNEURSA<\/span>","<span class=\"advgb-post-tax-term\">MIPLYFFA<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Market<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Niemann-Pick Disease Type C Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on May 2, 2025","modified":"Updated on Oct 9, 2025"},"absolute_dates_time":{"created":"Posted on May 2, 2025 5:35 pm","modified":"Updated on Oct 9, 2025 4:59 pm"},"featured_img_caption":"miplyffa-vs-aqneursa-in-niemann-pick-disease-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31580"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31580\/revisions"}],"predecessor-version":[{"id":33635,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31580\/revisions\/33635"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31583"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31580"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31580"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}